Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15431205 | 0.86 | ATR (0.39) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL4250286 | 0.85 | ATR (0.38) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL4256289 | 0.83 | PGK1 (0.35) | — | |
| SCHEMBL29659995 | 0.82 | P2RX3 (0.38) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL22298148 | 0.82 | P2RX3 (0.38) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL28389831 | 0.82 | P2RX3 (0.38) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL13659734 | 0.79 | ATR (0.41) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL22298147 | 0.79 | P2RX3 (0.35) | P2RX3ATRMAPKAPK2METAP1AAK1 | |
| SCHEMBL4250899 | 0.79 | ATR (0.37) | P2RX3ATRMAPKAPK2METAP1 | |
| SCHEMBL24344456 | 0.78 | ATR (0.36) | P2RX3ATRMAPKAPK2METAP1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2826778-B1 | Azaindole derivatives as CFTR modulators | VERTEX PHARMA (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2826778-B1 | Azaindole derivatives as CFTR modulators | VERTEX PHARMA (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9102672-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102672-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2118103-B1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2118103-B1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563573-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563573-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563573-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | P2RX3 146/4885ATR 3781/4885MAPKAPK2 3821/4885 |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | P2RX3 146/4885ATR 3781/4885MAPKAPK2 3821/4885 |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | P2RX3 146/4885ATR 3781/4885MAPKAPK2 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.